CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBDSAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today applauds President Trump's recent Executive Order (the "Order") to improve cannabidiol research to better inform patients and doctors. The Order directs agencies within the Department of Health and Human Services to allow Americans to benefit from access to appropriate full-spectrum CBD products based on research methods and models utilizing real-world evidence. Hemp-derived cannabinoid products have potential to improve patient symptoms for common ailments including pain, sleep and anxiety. This Order paves the way for hemp-derived cannabinoid products, primarily containing CBD, to be available under a regulated environment that would vastly improve product quality, safety and consumer confidence.
CV Sciences, Inc. Reports Third Quarter 2025 Financial ResultsSAN DIEGO, CA / ACCESS Newswire / November 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2025.
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2025, after the stock market closes on Thursday, November 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & FocusIgnite delivers a powerful blend of proven botanicals along with our award-winning CBD, designed to help men stay strong, sharp, and ready-at work, in the gym, and beyond.
CV Sciences, Inc. Reports Second Quarter 2025 Financial ResultsSAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2025.
CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 8, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2025, after the stock market closes on Wednesday, August 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 23, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today applauds Texas Governor Greg Abbott for vetoing Senate Bill 3, which would have created an effective ban on the sale of consumable hemp products across the state of Texas.
